New small molecule player with roots in David Liu's lab collects another $78M to fuel search for exosites
After working in CRISPR and then the microbiome field, Michael Bruce decided back in 2019 that it was time for a change.
“A lot of people joked and asked whether I was going to go and work for an RNA company, which, given all that’s happened over the last year or two, maybe that would have been a good idea,” he joked.
Instead, he dove into a space he hopes will become just as large: creating small molecules that target rarely pursued binding sites called exosites. And on Tuesday, his company Exo Therapeutics unveiled a $78 million Series B round to fuel its dash for the clinic.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.